- Home
- MCD vs NVS Comparison
MCD vs NVS Comparison
Compare MCD & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MCD | NVS |
|---|---|---|
| Founded | 1940 | 1895 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 217.9B | 254.8B |
| IPO Year | N/A | 1991 |
Fundamental Metrics
Financial Performance| Metric | MCD | NVS |
|---|---|---|
| Price | $304.22 | $129.35 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 25 | 3 |
| Target Price | ★ $326.35 | $118.00 |
| AVG Volume (30 Days) | ★ 3.3M | 1.6M |
| Earning Date | 11-05-2025 | 10-28-2025 |
| Dividend Yield | ★ 2.45% | 2.01% |
| EPS Growth | ★ 2.90 | N/A |
| EPS | ★ 11.72 | 7.30 |
| Revenue | $26,264,000,000.00 | ★ $56,372,000,000.00 |
| Revenue This Year | $4.17 | $9.44 |
| Revenue Next Year | $5.66 | $2.65 |
| P/E Ratio | $25.90 | ★ $17.72 |
| Revenue Growth | 1.25 | ★ 12.88 |
| 52 Week Low | $276.53 | $96.06 |
| 52 Week High | $326.32 | $134.00 |
Technical Indicators
Market Signals| Indicator | MCD | NVS |
|---|---|---|
| Relative Strength Index (RSI) | 48.45 | 52.38 |
| Support Level | $304.03 | $123.24 |
| Resistance Level | $313.30 | $131.19 |
| Average True Range (ATR) | 4.43 | 1.86 |
| MACD | 0.41 | 0.15 |
| Stochastic Oscillator | 28.62 | 55.76 |
Price Performance
Historical ComparisonAbout MCD McDonald's Corporation
McDonald's is the largest restaurant owner-operator in the world, with 2024 system sales of $131 billion across more than 43,000 stores and 115 markets. McDonald's pioneered the franchise model, building its footprint through partnerships with independent restaurant franchisees and master franchise partners around the globe. The firm earns roughly 60% of its revenue from franchise royalty fees and lease payments, with most of the remainder coming from company-operated stores across its three core segments: the United States, internationally operated markets, and international developmental/licensed markets.
About NVS Novartis AG
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.